Aequs Ltd reported a consolidated net loss of Rs 52.20 crore for Q2 FY27, even as its standalone entity remained profitable. The company also confirmed the rejection of its proposed subsidiary amalgamation scheme by the Ministry of Corporate Affairs and the approval of a Rs 65 crore preferential warrant issue to the promoter group.
Aequs Reports Q2 FY27 Results and Corporate Updates
Consolidated Q2 net loss stands at Rs 52.20 crore, while standalone profit is Rs 1.79 crore. Promoters to infuse Rs 65 crore via preferential warrant issuance.
Reader Takeaway: Strong core revenue growth in aerospace offset by consolidated losses; restructuring plans face regulatory setback.
What just happened
Aequs Ltd has released its financial results for the quarter ended September 30, 2026. While the standalone business reported a profit of Rs 1.79 crore on revenue of Rs 35.55 crore, the consolidated performance showed a net loss of Rs 52.20 crore against revenue of Rs 409.08 crore. Additionally, the company announced that the Regional Director of the Ministry of Corporate Affairs rejected its proposed scheme of amalgamation for its subsidiaries, AeroStructures Manufacturing, Aequs Engineered Plastics, and Aequs Force Consumer Products.
Why this matters
The divergence between standalone profitability and consolidated losses indicates significant overheads or operational costs within the group's wider structure. The rejection of the amalgamation scheme by the Ministry of Corporate Affairs requires the company to rethink its internal restructuring strategy, though management maintains this will not materially impact ongoing business operations.
Corporate Developments
The board has approved the issuance of 28,071,690 warrants to the Melligeri Private Family Foundation, a promoter group entity, for a total of Rs 65 crore. This capital infusion is a significant step for the company's liquidity position. Furthermore, the company successfully liquidated its subsidiary, Aequs Toys Hong Kong Private Limited, as part of a strategy to streamline its international footprint.
What to track next
Investors should closely monitor how the company addresses the consolidated losses and the potential for any revised restructuring plans following the regulatory rejection. The utilization of the funds raised via the preferential warrant issue will also be a key indicator of future capital allocation.